Abstract Number: 1557 • ACR Convergence 2021
Immunogenicity and Safety of an Inactivated Virus Vaccine Against SARS-CoV-2 in Patients with Autoimmune Rheumatic Diseases
Background/Purpose: Brazil is among the countries with the highest numbers of confirmed cases and deaths by COVID-19. CoronaVac (SARS-CoV-2 inactivated vaccine) has been largely used…Abstract Number: 1616 • ACR Convergence 2021
Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley
Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…Abstract Number: 1711 • ACR Convergence 2021
Increasing Preeclampsia Knowledge in SLE with a Specific Educational Tool: Preliminary Results
Background/Purpose: Pregnant women with systemic lupus erythematosus (SLE) are at high risk of preeclampsia, leading to substantial maternal and fetal morbidity. Aspirin reduces preeclampsia risk…Abstract Number: 1725 • ACR Convergence 2021
Higher Prevalence of Aspirin Use with a Specific Educational Tool in SLE Pregnancies: Preliminary Results
Background/Purpose: Pregnant women with SLE are at substantial risk of preeclampsia. Best international practice guidelines recommend aspirin (ASA) in this population, as it reduces preeclampsia…Abstract Number: 1896 • ACR Convergence 2021
Initial Results from the Implementation of a National Hydroxychloroquine Safe Prescribing Dashboard Within the Veterans Health Administration
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication for patients with lupus erythematosus, rheumatoid arthritis, and other autoimmune conditions. However, HCQ daily doses of ≥…Abstract Number: 0091 • ACR Convergence 2021
Vaccination of Patients with Chronic Inflammatory Rheumatic Diseases: An Analysis of Barriers and Facilitators in a Prospective Cohort
Background/Purpose: Patients (pts.) with chronic inflammatory rheumatic diseases (CIRD) are often not adequately protected against infectious diseases. As shown in an earlier study, less than…Abstract Number: 0100 • ACR Convergence 2021
Safety of COVID-19 Vaccines After First Vaccination in Patients with Rheumatic Diseases in a Patient Reported Survey
Background/Purpose: Among patients with rheumatic and musculoskeletal diseases (RMDs) and their treating physicians, concerns prevail about the effectiveness and safety of vaccination against COVID-19, especially…Abstract Number: 0114 • ACR Convergence 2021
The Safety Profile of SARS-CoV-2 Vaccines Among Patients with Immune-Mediated Rheumatic Diseases
Background/Purpose: The best strategy for the prevention of SARS-CoV-2 infection is vaccination. Both mRNA and vector vaccines have demonstrated a satisfactory safety profile in general…Abstract Number: 0116 • ACR Convergence 2021
COVID-19 mRNA Vaccine Side Effects Among Individuals with Rheumatic Disease
Background/Purpose: Over 135 million Americans were fully vaccinated to COVID-19 by June 2021, yet there was a paucity of data on side effects for those…Abstract Number: 0141 • ACR Convergence 2021
Who Gets Influenza Vaccinations Prior to and After a Diagnosis of RA? Results from the Canadian Early Arthritis Cohort (CATCH)
Background/Purpose: Annual influenza vaccination is recommended for adults with RA, but remains low in established RA. We examined influenza vaccination coverage in the year prior…Abstract Number: 0461 • ACR Convergence 2021
Plasmablast-derived Autoantibodies from Individuals At-risk for RA That Target RA-relevant Antigens Are Polyreactive with Arthritogenic Bacteria
Background/Purpose: Circulating autoantibodies like ACPA frequently develop years before symptoms of RA, during which the individual is at-risk for disease. Several lines of evidence suggest…Abstract Number: 0876 • ACR Convergence 2021
Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) often receive immunosuppressive treatment for many years, resulting in higher risk of infections, including COVID-19, and infections may…Abstract Number: 0957 • ACR Convergence 2021
Vitamin D and Marine n-3 Fatty Acid Supplementation and Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial
Background/Purpose: In observational studies, vitamin D has been inconsistently associated with reduced risk of several autoimmune diseases, and a large randomized, controlled trial has been…Abstract Number: 1077 • ACR Convergence 2021
Effectiveness of Non-Pharmacological Interventions to Promote Work Participation of People with Rheumatic and Musculoskeletal Diseases: A Systematic Review and Meta-Regression Analysis
Background/Purpose: Despite improvements in the treatment of rheumatic and musculoskeletal diseases (RMDs), reduced work participation persists when compared to the general population. A Task Force…Abstract Number: 1139 • ACR Convergence 2021
Fracture Liaison Service Outcomes at a Southern California County Hospital Highlights Need for Health System Improvements
Background/Purpose: Osteoporosis causes significant morbidity and mortality in the elderly. Despite the benefits of treatment, < 25% of elderly patients who fracture receive treatment. A…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 10
- Next Page »